IONS Stock Recent News

FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.

CARLSBAD, Calif. , Dec. 20, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P.

Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.

Ionis Pharmaceuticals is focused on developing and strengthening its position in the oligonucleotide therapeutics sector. Oligonucleotide therapeutics offer a novel method for treating diseases by altering gene expression and targeting specific genes or genetic sequences. Ionis Pharmaceuticals has a pipeline of potential commercial medicines, including Eplontersen, Olezarsen, and Donidalorsen, which have shown promising results in clinical trials.

Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.

CARLSBAD, Calif. , Nov. 3, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference on Tuesday, November 7, 2023 Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 Piper Sandler 35th Annual Healthcare Conference 2023 on Tuesday, November 28, 2023 BMO 2023 Growth & ESG Conference on Monday, December 4, 2023 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2023 Earnings Conference Call November 2, 2023 11:30 AM ET Company Participants Wade Walke - Senior Vice President, Investor Relations Brett Monia - Chief Executive Officer Onaiza Cadoret - Chief Global Product Strategy & Operations Officer Richard Geary - Chief Development Officer Beth Hougen - Chief Financial Officer Eugene Schneider - Chief Clinical Development Officer Conference Call Participants Gary Nachman - Raymond James Luca Issi - RBC Capital Yale Jen - Laidlaw & Company Allison Bratzel - Piper Sandler Yanan Zhu - Wells Fargo Kostas Biliouris - BMO Capital Markets Joseph Stringer - Needle & Company Myles Minter - William Blair David Lebowitz - Citi Operator Good morning, and welcome to Ionis' Third Quarter 2023 Financial Results Conference Call. As a reminder this call is being recorded.

Webcast scheduled for Thursday, November 2 at 11:30 a.m. Eastern Time CARLSBAD, Calif.

Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.

Ionis Pharmaceuticals (IONS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.